Advertisement

Studies for Identification of the Minimal Epitope(s) mimicked by the Synthetic Glucopeptide CSF114(Glc)

  • Francesca Nuti
  • Barbara Mulinacci
  • Elisa Peroni
  • Maria C. Alcaro
  • Ilaria Paolini
  • Francesco Benedetti
  • Alfonso Carotenuto
  • Francis Ciolli
  • Francesco Lolli
  • Mario Chelli
  • Paolo Rovero
  • Anna M. Papini
Part of the Advances in Experimental Medicine and Biology book series (volume 611)

Introduction

Molecules present in biological fluids, such as antibodies, can be identified as biomarkers and used to set up diagnostic/prognostic tools and for monitoring the effects of a therapeutic treatment. In the case of autoimmune disorders, such as Multiple Sclerosis (MS), antibodies have shown to reflect the presence, nature and intensity of the immune response. In particular, an antibody-mediated disease pattern seems to correlate with the relapsing-remitting form of Multiple Sclerosis. Antibodies may therefore be potentially useful as biomarker for the diagnosis, prognosis and classification of disease activity in MS and other immune-related diseases. Antibodies should be specific and they have to be detected by simple immunoassays, but unfortunately up to now there is no biomarker available fulfilling the criteria of a surrogate endpoint for Multiple Sclerosis. In order to discover more efficient tools for Multiple Sclerosis diagnosis, recent studies have focused on the use...

Keywords

Multiple Sclerosis Multiple Sclerosis Patient Original Sequence Binding Groove Competitive ELISA 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We thank FIRB 2005 RBIN04TWKN, PRIN 2005 PROT 2005032959 and the University of Florence for “Assegno Premiante” for Francesca Nuti.

References

  1. 1. (a)
    Lolli, F. et al. P.N.A.S. U.S.A., 102(29), 10273–10278, (2005)CrossRefGoogle Scholar
  2. 1. (b)
    Lolli, F. et al. J. Neuroimmunology, 167, 131–137, (2005)CrossRefGoogle Scholar
  3. 1. (c)
    Papini, A.M. Nat. Med. 11, 13, (2005)CrossRefGoogle Scholar
  4. 1. (d)
    Papini, A.M. et al. Granted U.S.A. Patent & PCT Application WO 03/000733 A2.Google Scholar
  5. 2.
    Mulinacci B., et al. In: Peptides 2004. Bridges Between Disciplines. M. Flegel, M. Fridkin, C. Gilon, J. Slaninova (Eds), Kenes International, Geneva, Switzerland, 593–594, (2005).Google Scholar
  6. 3.
    Alcaro M.C., et al. In: Peptides 2006. K. Rolka, P. Rekowski, J. Silberring (Eds.), Kenes International, Geneva, Switzerland (2007), pp 684–685.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Francesca Nuti
  • Barbara Mulinacci
  • Elisa Peroni
  • Maria C. Alcaro
    • 1
  • Ilaria Paolini
    • 1
  • Francesco Benedetti
  • Alfonso Carotenuto
    • 2
  • Francis Ciolli
  • Francesco Lolli
  • Mario Chelli
  • Paolo Rovero
  • Anna M. Papini
  1. 1.Toscana Biomarkers S.r.l.SienaItaly
  2. 2.Dept. of Pharmaceutical and Toxicological ChemistryUniversity of Naples “Federico II”NapoliItaly

Personalised recommendations